| Bunin, Nancy |
ALLELE, NCT03394365 / 2017-002949-30: Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Participants with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) After Failure of Rituximab or Rituximab and Chemotherapy |
|
|
| Recruiting | 3 | 66 | Europe, Canada, US, RoW | tabelecleucel, tab-cel®, ATA129, EBV-CTL | Atara Biotherapeutics | Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Solid Organ Transplant Complications, Lymphoproliferative Disorders, Allogeneic Hematopoietic Cell Transplant, Stem Cell Transplant Complications | 08/25 | 06/27 | | |
|
NCT02990819: Alpha/Beta T and CD19+ Depleted Peripheral Stem Cells for Patients With Primary Immunodeficiencies |
|
|
| Active, not recruiting | 2 | 60 | US | Apha/beta T and CD19+ cell depletion using CliniMACS device | Children's Hospital of Philadelphia, University of California, San Francisco | Immunodeficiencies, Immune Dysregulation Syndromes | 10/25 | 12/26 | | |
NCT03266640: Virus Specific Cytotoxic T-Lymphocytes (CTLs) for Refractory Cytomegalovirus (CMV) |
|
|
| Recruiting | 2 | 20 | US | viral specific cytotoxic t-lymphocytes, CMV CTLs | New York Medical College, Children's Hospital of Philadelphia, Medical College of Wisconsin, Nationwide Children's Hospital, Johns Hopkins University, University of California, San Francisco, Washington University School of Medicine, Indiana University, Children's Hospital Los Angeles | Cytomegalovirus Infections, Primary Immune Deficiency Disorder | 12/25 | 12/26 | | |
NCT03266627: Adenovirus-specific Cytotoxic T-lymphocytes for Refractory Adenovirus Infection |
|
|
| Recruiting | 2 | 20 | US | cytotoxic t-lymphocytes, viral specific CTLs | New York Medical College, Children's Hospital of Philadelphia, Medical College of Wisconsin, Nationwide Children's Hospital, Johns Hopkins University, University of California, San Francisco, University of Colorado, Denver, Indiana University, Washington University School of Medicine, University of California, Los Angeles | Adenovirus, Primary Immune Deficiency Disorder | 12/25 | 12/26 | | |
NCT03266653: EBV-specific Cytotoxic T-lymphocytes (CTLs) for Refractory EBV Infection |
|
|
| Recruiting | 2 | 20 | US | cytotoxic t-lymphocytes, CTLs | New York Medical College, Children's Hospital of Philadelphia, Medical College of Wisconsin, Nationwide Children's Hospital, Indiana University, Washington University School of Medicine, University of California, Los Angeles, University of California, San Francisco | Epstein-Barr Virus Infections, Primary Immune Deficiency Disorder | 12/25 | 12/26 | | |
| Active, not recruiting | 2 | 140 | US | Alpha Beta T cell depletion | Children's Hospital of Philadelphia | Leukemia, Lymphoma, Myelodysplasia | 10/25 | 10/26 | | |
NCT01050855: Reduced Intensity Conditioning (RIC) Regimen for Patients With Non-malignant Disorders |
|
|
| Active, not recruiting | 2 | 75 | US | RIC: Distal Campath, Reduced Intensity Conditioning Regimen, RIC:Intermediate Campath, RIC: Mini Busulfan | Children's Hospital of Philadelphia | Non Malignant Diseases, Immunodeficiencies, Hemoglobinopathies | 12/25 | 12/26 | | |
NCT01656603: Safety Study of Unlicensed IND Cord Blood Units Manufactured by the National Cord Blood Program for Unrelated Transplantation |
|
|
| Recruiting | 2 | 9999 | US | unlicensed CBU | New York Blood Center | Infusion Reactions | 12/25 | 12/25 | | |
| Recruiting | 2 | 64 | Canada, US | Busulfan, Cell processing for TCRαβ+/CD19+ depletion, CliniMACS | Michael Pulsipher, MD | SCID | 08/26 | 08/26 | | |
| Recruiting | 2 | 23 | US | CMV Cytotoxic T-Lymphocytes, CTLs, Anti-viral Therapy, valganciclovir, ganciclovir | New York Medical College | Congenital Cytomegaloviral (CMV) Disease | 10/27 | 10/28 | | |
NCT04197596: Treatment of Refractory BK Infections With Related Donor BK Specific Cytotoxic T-cells (CTLs) |
|
|
| Recruiting | 1/2 | 40 | US | BK CTL | New York Medical College, Children's Hospital of Philadelphia, Medical College of Wisconsin, Nationwide Children's Hospital, Johns Hopkins University, University of California, San Francisco | Viral Infection, Primary Immune Deficiency Disorder | 12/24 | 06/25 | | |
NCT04896606: SARS-CoV-2 CTLS for Mild to Moderate COVID-19 Disease |
|
|
| Recruiting | 1/2 | 50 | US | Standard of Care, SARS-CoV2-CTLS | New York Medical College, Children's Hospital of Philadelphia, Medical College of Wisconsin, Nationwide Children's Hospital | Covid19 | 12/24 | 12/25 | | |
BK-CTLs, NCT04293042: Treatment of BK Virus Infection With CTL Cells in Immunocompromised Transplant Patients |
|
|
| Recruiting | 1 | 20 | US | BK-virus specific CTLs | Children's Hospital of Philadelphia | BK Polyomavirus | 01/25 | 12/25 | | |
| Recruiting | 1 | 100 | US | Transplant of stem cells with CD3+/CD19+ depletion (CliniMACs), CliniMACs | Children's Hospital of Philadelphia | Leukemia, Inborn Errors of Metabolism, Bone Marrow Failure Syndromes, Immunodeficiencies, Immunodysregulation Polyendocrinopathy Enteropathy X-linked Syndrome | 01/25 | 01/27 | | |
NCT03810196: CD45RA Depleted Peripheral Stem Cell Addback for Viral or Fungal Infections Post TCRαβ/CD19 Depleted HSCT |
|
|
| Recruiting | N/A | 50 | US | CliniMACS Cell Processing System for TCRαβ + T Cell and CD45RA Depleted Peripheral Stem Cell Addback | Children's Hospital of Philadelphia | Acute Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndromes, Acute Lymphoblastic Leukemia, Mixed Lineage Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma, Juvenile Myelomonocytic Leukemia | 02/25 | 01/26 | | |
NCT03047746: Unrelated And Partially Matched Related Donor PSCT w/ T Cell Receptor (TCR) αβ Depletion for Patients With BMF |
|
|
| Recruiting | N/A | 50 | US | CliniMACs | Children's Hospital of Philadelphia | Acquired Aplastic Anemia, Paroxysmal Nocturnal Hemoglobinuria, Inherited Bone Marrow Failure Syndromes | 03/25 | 03/26 | | |
NCT01351545: A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) |
|
|
| Recruiting | N/A | 99999 | US | A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) | Center for International Blood and Marrow Transplant Research, National Marrow Donor Program | Hematologic Malignancies, Inherited Disorders of Metabolism, Inherited Abnormalities of Platelets, Histiocytic Disorders, Acute Myelogenous Leukemia (AML or ANLL), Acute Lymphoblastic Leukemia (ALL), Other Acute Leukemia, Chronic Myelogenous Leukemia (CML), Myelodysplastic (MDS) / Myeloproliferative (MPN) Diseases, Other Leukemia, Hodgkin Lymphoma, Non-hodgkin Lymphoma, Multiple Myeloma/ Plasma Cell Disorder (PCD), Inherited Abnormalities of Erythrocyte Differentiation or Function, Disorders of the Immune System, Autoimmune Diseases, Severe Aplastic Anemia | 10/41 | 10/41 | | |
| Wall, Donna |
NCT02875314: HeadStart4: Newly Diagnosed Children (<10 y/o) With Medulloblastoma and Other CNS Embryonal Tumors |
|
|
| Active, not recruiting | 4 | 250 | Canada, US, RoW | Induction, vincristine, cisplatin, cyclophosphamide, etoposide, high-dose methotrexate, Single Cycle Intensive Chemotherapy, Carboplatin, thiotepa, etoposide, Tandem 3 Cycle Intensive Chemotherapy, Carboplatin, thiotepa | Parth Patel, Children's of Alabama | Medulloblastoma, Central Nervous System Embryonal Tumors | 12/25 | 12/30 | | |
| Recruiting | 2/3 | 1800 | Europe, Canada, RoW | VP16, Etoposide, TBI, Thiotepa, Thio, Treosulfan, Treo, Fludarabine, Flu, Busulfan, Bu, ATG Thymoglobulin, ATG Thymo, Cyclophosphamide, Cy, Grafalon, Anti-human T-lymphocyte immunoglobulin | St. Anna Kinderkrebsforschung, ALL SCTped Forum, European Society for Blood and Marrow Transplantation, ALL-BFM Study Group, Assistance Publique - Hôpitaux de Paris, Dutch Childhood Oncology Group, Swiss Pediatric Oncology Group, Australian & New Zealand Children's Haematology/Oncology Group | Acute Lymphoblastic Leukaemia | 06/25 | 04/30 | | |
NCT05426252: Thal-Fabs: Reduced Toxicity Conditioning for High Risk Thalassemia |
|
|
| Recruiting | 1/2 | 20 | Canada | Abatacept, Orencia, Sirolimus, Rapamicin | The Hospital for Sick Children, Thalassemia Foundation of Canada | Thalassemia in Children | 12/25 | 12/26 | | |
| Carrum, George |
NCT03870750: Identifying Best Approach in Improving Quality of Life and Survival After a Donor Stem Cell Transplant in Older, Medically Infirm, or Frail Patients With Blood Diseases |
|
|
| Active, not recruiting | 2/3 | 455 | US | Supportive Palliative Care, Comfort Care, palliation, palliative care, palliative therapy, Palliative Treatment, Symptom Management, Symptoms Management, PA-Palliative Therapy, Clinical Management, Best Practice, standard of care, standard therapy, Allogeneic Hematopoietic Stem Cell Transplantation, Allogeneic Hematopoietic Cell Transplantation, Allogeneic Stem Cell Transplantation, HSC, HSCT, Stem Cell Transplantation, Questionnaire Administration, Quality-of-Life Assessment, Quality of Life Assessment, Survey Administration | Fred Hutchinson Cancer Center, National Cancer Institute (NCI), National Institutes of Health (NIH) | Hematopoietic and Lymphoid Cell Neoplasm, Non-Neoplastic Hematologic and Lymphocytic Disorder | 12/25 | 12/25 | | |
ACCESS, NCT04904588: HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide |
|
|
| Recruiting | 2 | 300 | US | Busulfan, Busulfex®, Fludarabine, Fludara®, Total-body irradiation, TBI, Cyclophosphamide, Cytoxan®, Melphalan, PBSC Hematopoietic Stem Cell Transplantation (HSCT), PBSC HSCT, PBSC HCT, PBSC Transplantation, Bone Marrow Hematopoietic Stem Cell Transplantation, BM HSCT, BM HCT, Bone Marrow Transplantation, Post-transplant Cyclophosphamide, Mesna, Mesnex®, Tacrolimus, Mycophenolate Mofetil, MMF, Cellcept®, Patient-Reported Outcomes | Center for International Blood and Marrow Transplant Research, National Marrow Donor Program | Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Mixed Phenotype Acute Leukemia, Acute Leukemia, Myelodysplastic Syndromes, Chronic Myelogenous Leukemia, Chronic Lymphocytic Leukemia, Lymphoma | 07/24 | 07/24 | | |
| Active, not recruiting | 2 | 12 | US | HST-NEETs, Bone Marrow Transplant | Catherine Bollard, National Heart, Lung, and Blood Institute (NHLBI), Blood and Marrow Transplant Clinical Trials Network, National Cancer Institute (NCI), National Marrow Donor Program, Children's National Research Institute | HIV Associated Lymphoma | 06/25 | 06/26 | | |
TETRAVI, NCT04013802: Multivirus CTL for Treatment of EBV, CMV, Adenovirus, and BK Infections Post Allogeneic SCT. |
|
|
| Recruiting | 1 | 47 | US | HLA-matched VSTs | Baylor College of Medicine, The Methodist Hospital Research Institute | Viral Infection | 05/25 | 05/25 | | |
NCT03601442: CTL019 Out of Specification MAP for ALL or DLBCL Patients |
|
|
| Available | N/A | | Canada, US, RoW | CTL019, tisagenlecleucel, Kymriah | Novartis Pharmaceuticals | Acute Lymphoblastic Leukemia (ALL), Diffuse Large B-cell Lymphoma (DLBCL) | | | | |
HAPLOTAB, NCT05236764: Haploidentical Hematopoietic Cell Transplantation Using TCR Alpha/Beta and CD19 Depletion |
|
|
| Recruiting | N/A | 47 | US | CliniMACS | Baylor College of Medicine, Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital Research Institute | Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia in Remission, Myelodysplastic Syndromes, Chronic Myeloid Leukemia, Hemophagocytic Lymphohistiocytoses, Primary Immunodeficiency Diseases, Hemoglobinopathies, Severe Aplastic Anemia, Cytopenia, Bone Marrow Failure Syndrome, Severe Chronic Active Epstein-Barr Virus Infection | 10/26 | 08/30 | | |
| Shaughnessy, Paul |
FELIX, NCT04404660: A Study of CD19 Targeted CAR T Cell Therapy in Adult Patients with Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL) |
|
|
| Active, not recruiting | 1/2 | 153 | NA | AUTO1, Obecabtagene autoleucel (obe-cel) | Autolus Limited | Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia | 05/25 | 05/25 | | |
|
CARBON, NCT04035434: A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory B-Cell Malignancies |
|
|
| Terminated | 1/2 | 62 | Europe, Canada, US, RoW | CTX110 | CRISPR Therapeutics AG | B-cell Malignancy, Non-Hodgkin Lymphoma, B-cell Lymphoma, Adult B Cell ALL | 10/24 | 10/24 | | |
| Recruiting | 1/2 | 225 | Europe, Japan, US, RoW | Rapcabtagene autoleucel single agent, Ibrutinib | Novartis Pharmaceuticals | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Diffuse Large B-cell Lymphoma, Acute Lymphoblastic Leukemia, Large B-cell Lymphoma | 06/27 | 05/28 | | |
NCT03601442: CTL019 Out of Specification MAP for ALL or DLBCL Patients |
|
|
| Available | N/A | | Canada, US, RoW | CTL019, tisagenlecleucel, Kymriah | Novartis Pharmaceuticals | Acute Lymphoblastic Leukemia (ALL), Diffuse Large B-cell Lymphoma (DLBCL) | | | | |
| Grimley, Michael |
ABA3, NCT04380740: Extended vs Short-term Abatacept Dosing for Graft Versus Host Disease Prophylaxis |
|
|
| Recruiting | 2 | 160 | US | Placebo, saline, Abatacept, orencia | Boston Children's Hospital, Bristol-Myers Squibb | Graft Vs Host Disease | 04/25 | 04/25 | | |
| Recruiting | 2 | 750 | US | Viral Specific VST Infusion | Children's Hospital Medical Center, Cincinnati | Viral Infection, Viral Reactivation, Infection in an Immunocompromised Host | 12/26 | 12/27 | | |
| Recruiting | 1/2 | 750 | US | Viral specific VST Infusion | Children's Hospital Medical Center, Cincinnati, Hoxworth Blood Center | Allogeneic Stem Cell Transplant, Viral Infection, Viral Reactivation | 01/27 | 01/27 | | |
| Ballen, Karen K |
ACCESS, NCT04904588: HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide |
|
|
| Recruiting | 2 | 300 | US | Busulfan, Busulfex®, Fludarabine, Fludara®, Total-body irradiation, TBI, Cyclophosphamide, Cytoxan®, Melphalan, PBSC Hematopoietic Stem Cell Transplantation (HSCT), PBSC HSCT, PBSC HCT, PBSC Transplantation, Bone Marrow Hematopoietic Stem Cell Transplantation, BM HSCT, BM HCT, Bone Marrow Transplantation, Post-transplant Cyclophosphamide, Mesna, Mesnex®, Tacrolimus, Mycophenolate Mofetil, MMF, Cellcept®, Patient-Reported Outcomes | Center for International Blood and Marrow Transplant Research, National Marrow Donor Program | Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Mixed Phenotype Acute Leukemia, Acute Leukemia, Myelodysplastic Syndromes, Chronic Myelogenous Leukemia, Chronic Lymphocytic Leukemia, Lymphoma | 07/24 | 07/24 | | |
NCT01656603: Safety Study of Unlicensed IND Cord Blood Units Manufactured by the National Cord Blood Program for Unrelated Transplantation |
|
|
| Recruiting | 2 | 9999 | US | unlicensed CBU | New York Blood Center | Infusion Reactions | 12/25 | 12/25 | | |
OPTIMIZE, NCT06001385: HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation with Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis |
|
|
| Recruiting | 2 | 190 | US | Busulfan, Busulfex®, Fludarabine, Fludara®, PBSC Hematopoietic Stem Cell Transplantation (HSCT), PBSC HSCT, PBSC HCT, PBSC Transplantation, PBSCT, Post-Transplant Cyclophosphamide, Cytoxan®, PTCy, Mesna, Mesnex®, Tacrolimus, Mycophenolate Mofetil, MMF, Cellcept®, Patient Reported Outcomes, PRO, Melphalan, Total-body irradiation, TBI, Cyclophosphamide | Center for International Blood and Marrow Transplant Research, National Marrow Donor Program | Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Leukemia, Myelodysplastic Syndromes, Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Myeloproliferative Neoplasm, Lymphoma, Chronic Myelomonocytic Leukemia, Pro-Lymphocytic Leukemia, Myelofibrosis | 02/26 | 06/26 | | |
ALL 001, NCT03962465: Phase I Study of Inotuzumab With Augmented BFM Re-Induction for Patients With Relapsed/Refractory B-cell ALL |
|
|
| Active, not recruiting | 1 | 36 | US | Inotuzumab ozogamicin, Besponsa, Prednisone Pill, Deltasone, Daunorubicin, Cerubidine, daunomycin, rubidomycin, Vincristine, Oncovin, Vincasar, Leurocristine, Cytarabine, Ara-C, Cytosar-U, Methotrexate, Otrexup, Rasuvo, Rheumatrex, Trexall, MTX, Amethopterin, Pegaspargase, Oncospar | University of Virginia, Pfizer, Vanderbilt University, University of Wisconsin, Madison, Virginia Commonwealth University | B-cell Acute Lymphoblastic Leukemia | 07/23 | 07/26 | | |
NCT05233618: Study of Tagraxofusp for Post-Transplant Maintenance for Patients With CD 123+ AML, MF and CMML (HSCT 002) |
|
|
| Recruiting | 1 | 44 | US | Tagraxofusp, SL-701, Elzonris | Karen Ballen, MD | Myelofibrosis, Chronic Myelomonocytic Leukemia, Acute Myeloid Leukemia | 07/26 | 10/26 | | |
NCT01351545: A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) |
|
|
| Recruiting | N/A | 99999 | US | A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) | Center for International Blood and Marrow Transplant Research, National Marrow Donor Program | Hematologic Malignancies, Inherited Disorders of Metabolism, Inherited Abnormalities of Platelets, Histiocytic Disorders, Acute Myelogenous Leukemia (AML or ANLL), Acute Lymphoblastic Leukemia (ALL), Other Acute Leukemia, Chronic Myelogenous Leukemia (CML), Myelodysplastic (MDS) / Myeloproliferative (MPN) Diseases, Other Leukemia, Hodgkin Lymphoma, Non-hodgkin Lymphoma, Multiple Myeloma/ Plasma Cell Disorder (PCD), Inherited Abnormalities of Erythrocyte Differentiation or Function, Disorders of the Immune System, Autoimmune Diseases, Severe Aplastic Anemia | 10/41 | 10/41 | | |
| Chan, Ka Wah |
NCT04863664: Lead EvaluAtion for Defibrillation and Reliability (LEADR) / Lead Evaluation for Defibrillation and Reliability in Left Bundle Branch Area Pacing (LEADR LBBAP) |
|
|
| Recruiting | N/A | 975 | Europe, Canada, Japan, US, RoW | Defibrillation (RV Implant), Defibrillation (LBBAP Implant) | Medtronic Cardiac Rhythm and Heart Failure | Tachyarrhythmia | 06/25 | 02/26 | | |
| Active, not recruiting | N/A | 464 | Europe, Canada, Japan, US, RoW | Aveir DR Leadless Pacemaker System | Abbott Medical Devices | Cardiac Pacemaker, Artificial, Cardiac Rhythm Disorder, Bradycardia | 08/23 | 11/25 | | |
NCT06563167: Detection and Prediction of Clinically Significant Pneumothorax After Image-guided Transthoracic Lung Biopsy |
|
|
| Not yet recruiting | N/A | 330 | RoW | CXR | Chinese University of Hong Kong | Lung Biopsy | 12/24 | 12/25 | | |
| Not yet recruiting | N/A | 400 | NA | Mycobacterium tuberculosis (MTB) cell-free DNA (cfDNA), Mycobacterium tuberculosis PCR | Chinese University of Hong Kong | Tuberculosis, Pleural | 03/26 | 09/26 | | |
| Recruiting | N/A | 62 | RoW | Mycobacterium tuberculosis (MTB) cell-free DNA (cf-DNA), Mycobacterium tuberculosis PCR | Chinese University of Hong Kong | Tuberculosis, Pleural | 09/24 | 09/25 | | |
NCT05351515: Prevalence of Non-alcoholic Fatty Liver Disease Among Non-obese Obstructive Sleep Apnea by Using Transient Elastography |
|
|
| Recruiting | N/A | 1000 | RoW | | Chinese University of Hong Kong | Sleep Apnea, Obstructive, Fatty Liver | 01/25 | 01/25 | | |
| Not yet recruiting | N/A | 350 | RoW | | Chinese University of Hong Kong | Tuberculosis, Pleural | 02/26 | 02/26 | | |
NCT05397717: Prospective Study on Clinical Outcomes of Spontaneous Pneumothorax |
|
|
| Recruiting | N/A | 349 | RoW | observational | Chinese University of Hong Kong | Pneumothorax, Spontaneous | 09/25 | 09/26 | | |
NCT05759117: Prospective Evaluation of Patients With Pleural Effusion |
|
|
| Recruiting | N/A | 1000 | RoW | thoracentesis, chest drain insertion | Chinese University of Hong Kong | Pleural Effusion | 03/26 | 03/26 | | |
| Recruiting | N/A | 115 | RoW | 16S rRNA gene amplicon sequencing, Shotgun metagenomic sequencing | Chinese University of Hong Kong | Parapneumonic Effusion | 05/26 | 05/27 | | |
| Investigator, Principal |
| Completed | 4 | 144 | Europe | Opicapone 50 mg, BIA 9-1067, Placebo | Bial - Portela C S.A., Bial - Portela & Ca, S.A. | Parkinson Disease | 02/24 | 02/24 | | |
NCT04248205: Ketamine for Post-operative Analgesia in Hemorrhoidectomy |
|
|
| Recruiting | 4 | 100 | US | Ketamine | University of Oklahoma | Hemorrhoids | 01/25 | 07/25 | | |
NCT05400369: A Study to Evaluate the Efficacy and Safety of Sitafloxacin in Adult Subjects With Acute Exacerbation of Chronic Obstructive Pulmonary Disease |
|
|
| Completed | 4 | 140 | RoW | Sitafloxacin, Gracevit, Moxifloxacin Hydrochloride, Avelox | Daiichi Sankyo | COPD Exacerbation Acute | 09/24 | 09/24 | | |
TrEAT_TD2, NCT05677282: Single Dose Antibiotic Treatment of Acute Watery Diarrhea, Rifaximin Versus Azithromycin, with Loperamide Adjunct |
|
|
| Recruiting | 4 | 150 | RoW | Rifaximin 550 MG, Azithromycin 500 MG, Loperamide | Henry M. Jackson Foundation for the Advancement of Military Medicine, Infectious Diseases Clinical Research Program, Uniformed Services University of the Health Sciences | Diarrhoea;Acute, Diarrhea Travelers | 09/25 | 12/25 | | |
NCT06397781: Effect of S. Aureus Skin Decolonization on Disease Severity in Atopic Dermatitis Patients |
|
|
| Not yet recruiting | 4 | 100 | US | Skin Cleanser Combination No.1 | Boston Children's Hospital | Atopic Dermatitis | 12/28 | 12/28 | | |
NCT06793358: Use of Remimazolam and Fentanyl for Procedural Sedation in Patients Undergoing Dental Extraction |
|
|
| Not yet recruiting | 4 | 40 | US | fentanyl and Remimazolam | Indiana University, Indiana University Health | Dental Extraction | 01/26 | 03/26 | | |
POUR, NCT04994431: Post-Operative Urinary Retention () in Thoracic Surgery Patients Receiving Prophylactic Tamsulosin |
|
|
| Terminated | 4 | 109 | US | Tamsulosin Hydrochloride | University of Massachusetts, Worcester, UMass Memorial Health Care | Thoracic Diseases, Urinary Retention | 10/23 | 10/23 | | |
NCT02932410 / 2016-001062-28: A Study to Assess Whether Macitentan Delays Disease Progression in Children With Pulmonary Arterial Hypertension (PAH) |
|
|
| Active, not recruiting | 3 | 165 | Europe, Canada, US, RoW | Macitentan, ACT-064992, Standard-of-care | Actelion | Pulmonary Arterial Hypertension | 08/24 | 07/25 | | |
| Active, not recruiting | 3 | 590 | Europe, Canada, Japan, US, RoW | DS-1062a, Datopotamab deruxtecan (Dato-DXd), Docetaxel | Daiichi Sankyo, AstraZeneca | Non-small Cell Lung Cancer | 05/24 | 06/25 | | |
|
|
IDeate-Lung02, NCT06203210: A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer |
|
|
| Recruiting | 3 | 540 | Europe, Canada, Japan, US, RoW | Ifinatamab deruxtecan, I-DXd, Topotecan, Amrubicin, Lurbinectedin | Daiichi Sankyo, Merck Sharp & Dohme LLC | Small Cell Lung Cancer | 04/27 | 02/29 | | |
TNX-N, NCT03503136: Nedaplatin Versus Cisplatin and Capecitabine Versus Fluorouracil in IC + CCRT for Locoregionally Advanced NPC |
|
|
| Not yet recruiting | 3 | 632 | RoW | docetaxel, nedaplatin, and capecitabine, TNX induction chemotherapy, nedaplatin, N, docetaxel, cisplatin, and fluorouracil, TPF induction chemotherapy, cisplatin, P, docetaxel, cisplatin, and capecitabine, TPX induction chemotherapy, docetaxel, nedaplatin, and fluorouracil, TNF induction chemotherapy | Sun Yat-sen University, Tongji Hospital, Wuhan Union Hospital, China, Peking University, Air Force Military Medical University, China, Second Affiliated Hospital of Soochow University, The First Affiliated Hospital of Guangdong Pharmaceutical University, First People's Hospital of Foshan, Fifth Affiliated Hospital, Sun Yat-Sen University, Cancer Hospital of Guizhou Province, Xiangya Hospital of Central South University, Jilin Provincial Tumor Hospital, Henan Cancer Hospital, Hunan Cancer Hospital, Cancer Hospital of Guangxi Medical University, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Zhejiang Cancer Hospital | Nasopharyngeal Carcinoma | 06/24 | 06/26 | | |
NCT05839899: Mifepristone and Misoprostol for Undesired Pregnancy of Unknown Location |
|
|
| Recruiting | 3 | 50 | US | Mifepristone plus one dose Misoprostol, Mifepristone plus two doses Misoprostol | Planned Parenthood League of Massachusetts | Abortion | 07/24 | 09/24 | | |
| Active, not recruiting | 3 | 586 | Europe, Canada, Japan, US, RoW | Patritumab Deruxtecan, HER3-DXd, U3-1402, Platinum-based chemotherapy | Daiichi Sankyo, Merck Sharp & Dohme LLC | Nonsquamous Non-small Cell Lung Cancer, EGFR L858R, EGFR Exon 19 Deletion | 05/24 | 06/26 | | |
CYPRESS, NCT05696717: Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic NOH in Participants with Multiple System Atrophy |
|
|
| Recruiting | 3 | 102 | Europe, Canada, US, RoW | Ampreloxetine, TD-9855, Placebo | Theravance Biopharma | Symptomatic Neurogenic Orthostatic Hypotension, MSA - Multiple System Atrophy | 12/24 | 01/27 | | |
NCT06672016: Study to Evaluate Contraceptive Efficacy and Safety of a Progestin Only Patch in Women of Childbearing Potential |
|
|
| Not yet recruiting | 3 | 1500 | US | Transdermal system containing progestin | Mylan Pharmaceuticals Inc | Female Contraception | 03/27 | 04/27 | | |
| Not yet recruiting | 3 | 615 | RoW | Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection | Beijing VDJBio Co., LTD. | Rheumatoid Arthritis (RA) | 12/25 | 12/26 | | |
LIBERTY, NCT06716814: Study to Provide Continued Access to Treatment for Patients Completing a Previous Trial With Efanesoctocog Alfa |
|
|
| Not yet recruiting | 3 | 78 | Europe | Efanesoctocog alfa, BIVV001, Altuvoct, Altuviiio, Recombinant coagulation factor VIII Fc-von-Willebrand Factor-XTEN fusion protein (rFVIIIFc-VWF-XTEN) | Swedish Orphan Biovitrum, PSI CRO | Severe Haemophilia A | 08/26 | 08/26 | | |
| Active, not recruiting | 3 | 899 | Europe, Canada, Japan, US, RoW | Tafasitamab, Monjuvi, Lenalidomide, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Tafasitamab placebo, Lenalidomide placebo | Incyte Corporation | Diffuse Large B-cell Lymphoma | 06/25 | 05/26 | | |
|
|
|
| Completed | 3 | 1 | US | StrataGraft | Stratatech, a Mallinckrodt Company, Biomedical Advanced Research and Development Authority | Skin Wound, Burns, Trauma-related Wound | 05/24 | 05/24 | | |
| Active, not recruiting | 3 | 490 | Europe, Japan, RoW | Trastuzumab deruxtecan, T-DXd, DS-8201a, ENHERTU®, Ramucirumab, CYRAMZA®, Paclitaxel | Daiichi Sankyo, AstraZeneca | Gastric Cancer, Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | 10/25 | 02/26 | | |
|
|
|
|
NCT05847348: 68Ga-PSMA-11 Efficacy in Detecting BCR Prostate Cancer in Chinese Patients |
|
|
| Recruiting | 3 | 110 | RoW | 68Ga-PSMA-11, Illucix, gallium Ga 68 Gozetotide, PET/CT or PET/MRI, Imaging by PET | Telix Pharmaceuticals (Innovations) Pty Limited, Grand Pharmaceutical (China) Co., Ltd. | Biochemical Recurrence of Malignant Neoplasm of Prostate, Prostate Cancer, BCR Prostate Carcinoma | 12/25 | 07/26 | | |
| Active, not recruiting | 3 | 1600 | Europe, Canada, Japan, US, RoW | DS-8201a, Trastuzumab deruxtecan (T-DXd), T-DM1, Trastuzumab emtansine (T-DM1) | Daiichi Sankyo, AstraZeneca, NSABP Foundation Inc, German Breast Group, Spanish Breast Cancer Research Group (SOLTI) | HER2-Positive Primary Breast Cancer, Residual Invasive Breast Cancer | 12/25 | 12/30 | | |
|
|
FREEDOM, NCT05817812: A Study Evaluating Physical Activity and Joint Health in Severe Haemophilia A Patients ≥12 Years Treated Once Weekly With Efanesoctocog Alfa |
|
|
| Active, not recruiting | 3 | 93 | Europe, RoW | Efanesoctocog alfa, BIVV001 | Swedish Orphan Biovitrum, Syneos Health | Hemophilia A, Severe | 05/26 | 05/26 | | |
TROPION-Lung07, NCT05555732: Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer |
|
|
| Recruiting | 3 | 1170 | Europe, Canada, Japan, US, RoW | Datopotamab Deruxtecan, Dato-DXd, Pembrolizumab, KEYTRUDA®, Pemetrexed, Alimta, Pemfexy, Carboplatin, Cisplatin | Daiichi Sankyo, AstraZeneca, Merck Sharp & Dohme LLC | Metastatic Non Small Cell Lung Cancer | 08/27 | 08/27 | | |
DESTINY-Breast15, NCT05950945: Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer |
|
|
| Recruiting | 3 | 250 | Europe, US, RoW | Trastuzumab Deruxtecan, T-DXd, DS-8201a (trastuzumab derextecan), Enhertu® | Daiichi Sankyo, AstraZeneca | Breast Cancer | 10/27 | 10/27 | | |
| Recruiting | 3 | 740 | Europe, Canada, Japan, US, RoW | Datopotamab Deruxtecan, Dato-DXd, Pembrolizumab, KEYTRUDA® | Daiichi Sankyo, AstraZeneca, Merck Sharp & Dohme LLC | Metastatic Non Small Cell Lung Cancer | 02/28 | 04/28 | | |
|
|
ARTEMIS, NCT04797884: Electromagnetic Fields Versus Placebo For Child-Pugh A and B Patients With Advanced Hepatocellular Carcinoma |
|
|
| Recruiting | 2/3 | 166 | US | TheraBionic Device, Placebo Device, Quality of Life Assessment | THERABIONIC INC., National Cancer Institute (NCI) | Hepatocellular Carcinoma | 10/24 | 10/24 | | |
FORTIFI-HN01, NCT06788990: a Study of Ficerafusp Alfa (BCA101) or Placebo in Combination with Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC |
|
|
| Recruiting | 2/3 | 650 | US | Ficerafusp alfa, Pembrolizumab (KEYTRUDA®), Placebo | Bicara Therapeutics | Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma | 04/28 | 07/29 | | |
TRIPHASE, NCT06101745: Trial to Visualize the Ureters With Nizaracianine Triflutate in Adults Undergoing Abdominopelvic Surgery |
|
|
| Recruiting | 2/3 | 336 | Europe | Nizaracianine Triflutate, ZW800-1, Placebo Comparator, Sugar | Curadel Surgical Innovations, Inc., Leiden University Medical Center, Erasmus Medical Center | Injury of Ureter During Surgery (Disorder) | 10/25 | 11/25 | | |
| Terminated | 2 | 16 | Europe, Canada, US, RoW | Belcesiran, Placebo | Dicerna Pharmaceuticals, Inc., a Novo Nordisk company | Alpha 1-Antitrypsin Deficiency | 12/23 | 05/24 | | |
AAVIATE, NCT04514653: RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD) |
|
|
| Recruiting | 2 | 115 | US | Ranibizumab, RGX-314 Dose 1, Combination Product, RGX-314 Dose 2, RGX-314 Dose 3, Local Steroid, Topical Steroid | AbbVie, AbbVie | Neovascular Age-Related Macular Degeneration (nAMD) | 10/25 | 08/26 | | |
| Completed | 2 | 60 | US | RGX-314 | AbbVie | Neovascular Age-related Macular Degeneration, Wet Macular Degeneration, Wet Age-related Macular Degeneration | 10/23 | 03/24 | | |
Orchid 1, NCT06132919: Efficacy and Safety of MC2-25 Cream & Vehicle in Women With Vulvar Lichen Sclerosus (VLS) |
|
|
| Recruiting | 2 | 40 | Europe | MC2-25 cream, MC2-25 vehicle | MC2 Therapeutics | Vulvar Lichen Sclerosus | 11/24 | 11/24 | | |
| Completed | 2 | 13 | US | AG Tx, Meshed Autograft, SOMA Tx, StrataGraft skin tissue Overlay of Meshed Autograft (SOMA) | Stratatech, a Mallinckrodt Company | Full Thickness Thermal Burn | 03/24 | 03/24 | | |
| Recruiting | 2 | 400 | Europe, Japan, US, RoW | HER3-DXd, Patritumab Deruxtecan, U3-1402 | Daiichi Sankyo, Merck Sharp & Dohme LLC | Advanced Solid Tumor, Melanoma, Head and Neck Cancer, Gastric Cancer, Ovarian Carcinoma, Cervical Cancer, Endometrial Cancer, Bladder Cancer, Esophageal Cancer, Pancreatic Carcinoma, Prostate Cancer | 06/25 | 04/26 | | |
NCT05198310 / 2022-000169-42: Study to Assess the Safety, Pharmacokinetics, and Efficacy of KPL-404 in Participants With Rheumatoid Arthritis With Inadequate Response or Intolerance to at Least One Biologic Disease-modifying Anti-rheumatic Drug or a Janus Kinase Inhibitor |
|
|
| Completed | 2 | 145 | Europe, US, RoW | KPL-404, Placebo | Kiniksa Pharmaceuticals, Ltd., Kiniksa Pharmaceuticals, Ltd. | Arthritis, Rheumatoid | 02/24 | 05/24 | | |
| Recruiting | 2 | 90 | US | Hydroxypropyl Beta Cyclodextrin, Trappsol Cyclo, Placebo, 0.5N saline | Cyclo Therapeutics, Inc., Cyclo Therapeutics Inc. | Alzheimer's Disease | 03/24 | 03/24 | | |
| Completed | 2 | 65 | Europe, US | DS-1211b, Placebo | Daiichi Sankyo, PXE International | Pseudoxanthoma Elasticum | 11/23 | 11/23 | | |
IDeate-PanTumor02, NCT06330064: A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors |
|
|
| Recruiting | 2 | 520 | Europe, Japan, US, RoW | Ifinatamab deruxtecan, I-DXd | Daiichi Sankyo, Merck Sharp & Dohme LLC | Recurrent or Metastatic Solid Tumors | 07/28 | 07/28 | | |
MAST, NCT06355583: Intestinal Microbiota Transplant Prior to Allogeneic Stem Cell Transplant () Trial |
|
|
| Not yet recruiting | 2 | 50 | Europe | EBX-102, IMT capsules, Placebo | Imperial College London | Acute Lymphoblastic Leukaemia, Acute Leukemia of Ambiguous Lineage, Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Acute Myeloid Leukemia | 02/26 | 05/27 | | |
NCT04870905: Tisleilizumab (PD-1 Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma |
|
|
| Not yet recruiting | 2 | 100 | RoW | Tis-U-Sol | Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Union hospital of Fujian Medical University, Zhujiang Hospital, Guangdong Provincial People's Hospital | Nasopharyngeal Neoplasms | 05/24 | 05/26 | | |
| Active, not recruiting | 2 | 187 | Europe, Japan, US, RoW | Ifinatamab Deruxtecan (I-DXd), DS-7300a | Daiichi Sankyo, Merck Sharp & Dohme LLC | Extensive-stage Small-cell Lung Cancer | 01/25 | 04/25 | | |
| Recruiting | 2 | 32 | RoW | SPG302, Placebo | Spinogenix | Schizophrenia | 06/25 | 10/25 | | |
CBeyond, NCT06577090: Study to Evaluate the Effect on Obesity of Once Weekly Nimacimab Injection and Once Weekly Nimacimab Injection Co-administered With Semaglutide Injection Versus Placebo |
|
|
| Recruiting | 2 | 120 | US | Nimacimab injection, Nimacimab placebo injection, semaglutide injection | Skye Bioscience, Inc., Bird Rock Bio Sub, Inc. | Obesity | 08/25 | 01/26 | | |
NCT05029336: Autologous Stem Cell Transplant (ASCT) for Autoimmune Diseases |
|
|
| Recruiting | 2 | 20 | US | Depletion of CD3/CD19 in an autologous stem cell transplant, CD3/CD19 depletion using cliniMACs device | Stephan Grupp MD PhD | Systemic Lupus Erythematosus, Systemic Sclerosis | 12/26 | 05/31 | | |
| Recruiting | 2 | 64 | US | Bevonescein, ALM-488 | Alume Biosciences, Inc. | Surgery, Nerve Injury, Imaging | 06/25 | 09/25 | | |
NCT04935762: A Study of CST-103 Co-administered With CST-107 in Subjects With Parkinson's Disease Having Freezing of Gait (CLIN-012) |
|
|
| Withdrawn | 2 | 25 | RoW | CST-103, CST-107, matching placebo | CuraSen Therapeutics, Inc. | Freezing of Gait Symptoms in Parkinson's Disease | 12/24 | 03/25 | | |
| Not yet recruiting | 2 | 200 | Japan, US | Raludotatug deruxtecan, R-DXd | Daiichi Sankyo, Merck Sharp & Dohme LLC | Advanced Solid Tumor, Metastatic Solid Tumors | 09/27 | 09/27 | | |
NCT04977024: SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer |
|
|
| Recruiting | 2 | 240 | US | COVID-19 Vaccine, Diagnostic Laboratory Biomarker Analysis, Synthetic MVA-based SARS-CoV-2 Vaccine GEO-CM04S1, COH04S1, SARS-CoV-2 Vaccine COH04S1, sMVA-based SARS-CoV-2 Vaccine COH04S1, GEO-CM04S1 | GeoVax, Inc., National Cancer Institute (NCI) | COVID-19 Infection, Hematopoietic and Lymphoid System Neoplasm, Leukemia, Lymphoma, Plasma Cell Myeloma | 12/26 | 12/27 | | |
STEP, NCT06594393: A Phase 2 Study of TCP-25 Gel in Patients with Epidermolysis Bullosa, -study |
|
|
| Not yet recruiting | 2 | 26 | Europe | TCP-25 gel, Vehicle (placebo) | Xinnate AB | Epidermolysis Bullosa (EB) | 06/26 | 06/26 | | |
NCT06038578: A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer |
|
|
| Recruiting | 2 | 146 | Japan, US, RoW | TRK-950, Ramucirumab, CYRAMZA®, Paclitaxel | Toray Industries, Inc | Gastric Adenocarcinoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma | 08/25 | 08/25 | | |
